Tempus AI, Inc. (TEM)
Summary
Tempus AI: Building Ultimate Healthcare Data Dominance
Tempus AI, Inc. earns a Strong Buy rating due to its transformation into a healthcare data giant with high-margin, rapidly growing data services. TEM's Q1 2026 data segment revenue surged 40% YoY to $87M, with robust bookings and visibility, positioning the segment for $500M+ revenue in 2026. MRD testing volume rose 500% YoY, driven by a highly sensitive, reimbursed test partnership with Personalis, fueling valuable data acquisition for pharma clients.
Tempus AI: Buy On Diagnostics Momentum And AI Platform Expansion
Tempus receives a Buy rating, leveraging a unique AI-driven diagnostics and data platform with expanding FDA-approved offerings. Recent FDA approval for xT CDx's tumor-only indication and the upcoming xH assay broaden TEM's clinical reach and addressable markets. AI-powered Lens and Next platforms drive adoption among top biopharma and improve clinical outcomes, reinforcing TEM's data flywheel and competitive moat.
Should You Retain Tempus AI Stock In Your Portfolio Now?
TEM's diagnostics growth and expanding data deals support momentum, but sizable GAAP losses and execution challenges could keep shares volatile.
Tempus AI, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 245 | $14,356.86 | $14,170.8 | -$186.06 | -1.3% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,859 | $146,660.93 | $107,134.17 | -$39,526.76 | -26.95% |
| YA Yinka Akinsola Blue Trust Inc. | 300 | $14,472 | $17,051.94 | $2,579.94 | 17.83% |
 Jeff Ameen Spire Wealth Management | 91 | $4,527.54 | $5,209.75 | $682.21 | 15.07% |
| CPS Chow Pak Sun Gordian Capital Singapore Pte Ltd. | 12,500 | $811,850 | $711,250 | -$100,600 | -12.39% |
Tempus AI, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Tycho Peterson Jefferies | -376.55 | $17,930.11 | $21,557.7 | -$3,627.59 | -20.23% |
 Mark Massaro BTIG | 33.51 | $1,657.69 | $1,918.39 | $260.7 | 15.73% |
Tempus AI, Inc. (TEM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tempus AI, Inc. ever had a stock split?
Tempus AI, Inc. Profile
| Technology Hardware, Storage & Peripherals Industry | Information Technology Sector | Eric Lefkofsky CEO | NASDAQ (NGS) Exchange | 88023B103 CUSIP |
| US Country | 3,800 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Tempus AI, Inc. stands as a vanguard healthcare technology company, specializing in delivering cutting-edge diagnostic solutions. Established in 2015 and based in Chicago, Illinois, its operations encompass a comprehensive range of molecular and anatomic pathology tests. Initially known as Tempus Labs, Inc., the company underwent a rebranding to Tempus AI, Inc. in January 2023. Its offerings are designed to support healthcare providers, pharmaceutical entities, biotechnology firms, researchers, and other third-party organizations. Its mission revolves around the fusion of clinical data and artificial intelligence to forge advancements in healthcare outcomes.
Products and Services
Tempus AI, Inc. has curated a diverse portfolio of products and services, each tailored to address various aspects of healthcare diagnostics and research:
- Next Generation Sequencing Diagnostics: Leveraging comprehensive genomic profiling to aid in the identification of DNA mutations responsible for cancers, guiding personalized treatment plans.
- Polymerase Chain Reaction (PCR) Profiling: Enabling rapid detection and identification of genetic material from a specific organism, useful in diagnosing infectious diseases, among others.
- Molecular Genotyping: Provides essential data for understanding genetic predispositions to diseases, facilitating preventive healthcare strategies.
- Insights: Offers a vast library of de-identified clinical, molecular, and imaging data, coupled with a suite of analytical services. It provides pharmaceutical and biotechnology companies with valuable data analytics capabilities, by employing advanced analytical and cloud-compute technologies.
- Trials: A service designed to match clinical trials with suitable candidates, thus accelerating the drug development process for pharmaceutical companies.
- Next; Algos: This suite presents algorithmic tests specifically in the field of oncology, enhancing the speed and accuracy of cancer diagnosis and treatment planning.
- Hub: A comprehensive platform for healthcare providers, facilitating easy ordering, management, and receipt of tests and patient results through both desktop and mobile interfaces.
- Lens: Exclusively for researchers and scientists, this platform allows the exploration, access, and analysis of Tempus's rich data sets, fostering innovation in medical research.
